Treatment-emergent neuroendocrine prostate cancer: Clinical relevance and molecular pathogenesis
The Open University, Milton Keynes, MK7 6AA
One day symposium hosted by the Open University.
- 9:00-10:00 Registration (tea, coffee, biscuits)
Session 1 : CLINICAL ASPECTS OF TREATMENT-EMERGENT NEUROENDOCRINE PROSTATE CANCER
Session Chair: Dr Sushila Rigas, The Open University
- 10-10.15 Welcome, Dr Martin Bootman, Director of Research LHCS, The Open University
- 10.15-11:00 Clinical characterization of treatment-emergent NEPC, Prof Hardev Pandha, Director of Surrey Cancer Centre
- 11:00-11.30.Therapeutic opportunities for neuroendocrine prostate cancer, Dr Pasquale Rescigno, Institute of Cancer Research, London
- 11.30-12.30 Panel discussion: treatment-emergent NEPC: a new challenge for clinicians and researchers, Dr Joo-Hee Sir, Cancer Research UK; Dr Mark Eccleston, Volition; Dr Rebecca Mather, Open University
- 12.30-2.00 Lunch and poster session
Session 2 : MOLECULAR MECHANSISMS OF NEUROENDOCRINE TRANS-DIFFERENTIATION
Session Chair: Dr Mario Colombo, Italian National Cancer Institute
- 2.00-2.45 The nature of neuroendocrine trans-differentiation: lessons learned from patient-derived xenografts, Prof YZ Wang, BC Cancer Agency, Canada
- 2.45-3.15 The long non-coding RNA landscape of neuroendocrine prostate cancer, Dr Francesco Crea, The Open University
- 3.15-3.45 The role of tumour microenvironment in neuroendocrine prostate cancer, Dr Elena Jachetti, Italian National Cancer Institute
- 4.00-4.30 Feedback opportunity
- 4.30-6:00 Networking(tea, coffee, biscuits)
Early registration is open; see http://www.open.ac.uk/science/life-health-chemical-sciences/nepc-2019 for instructions.
Please address any queries to firstname.lastname@example.org.